Loading...
1 / 2
DSIP
Add to Wishlist
Delta-Sleep Inducing Peptide — Neuromodulatory & Sleep Research
In Stock
Select Size
$60.00$72.00
You Save
$12.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated from the cerebral venous blood of rabbits during electrically induced slow-wave sleep by Schoenenberger and Monnier in 1977. At the molecular level, DSIP modulates multiple neurotransmitter systems including GABAergic, glutamatergic, and serotonergic pathways, and interacts with the hypothalamic-pituitary-adrenal (HPA) axis by reducing corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion, thereby attenuating cortisol production and stress-related arousal. Published peer-reviewed research demonstrates that DSIP promotes the onset and duration of delta-wave (Stage 3-4) slow-wave sleep — the restorative sleep phase critical for growth hormone secretion, immune function, tissue repair, and memory consolidation — without suppressing REM sleep architecture as benzodiazepine sleep aids do. Additional investigations have explored DSIP's analgesic properties through modulation of enkephalinase activity, its antioxidant effects through upregulation of superoxide dismutase, and its ability to normalize disrupted circadian cortisol and melatonin rhythms in models of chronic stress and shift-work sleep disorders. What distinguishes DSIP from conventional sleep-promoting compounds is its physiological neuromodulatory mechanism that restores natural sleep architecture rather than pharmacologically inducing sedation, and its multi-system regulatory activity spanning sleep, stress, pain, and hormonal balance. Current scientific investigation continues in sleep disorder models, chronic stress physiology, opioid withdrawal, and the interface between sleep quality and metabolic health.
Handling & Storage
Published research protocols reference subcutaneous or intranasal administration. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference 100-200mcg doses. Consult applicable literature for specific research applications.
Research Applications
Delta Sleep Promotion
DSIP promotes the onset and duration of Stage 3-4 slow-wave (delta) sleep characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations, without suppressing REM sleep architecture. Published sleep physiology research indicates that delta sleep is the primary phase for pulsatile growth hormone secretion, immune cytokine regulation, glymphatic brain waste clearance, and synaptic homeostasis through downscaling — making DSIP's selective delta-wave promotion mechanistically distinct from sedative-hypnotic drugs.
Initial effects within first month
Stress Hormone Modulation
Published research demonstrates that DSIP modulates the hypothalamic-pituitary-adrenal (HPA) axis by reducing corticotropin-releasing hormone (CRH) release from the paraventricular nucleus and subsequent ACTH secretion from the anterior pituitary, leading to attenuated cortisol production without complete adrenal suppression. This mechanism normalizes the disrupted cortisol circadian rhythm (elevated evening cortisol, blunted cortisol awakening response) that characterizes chronic stress, insomnia, and metabolic dysfunction.
Initial effects within first month
Sleep Pattern Normalization
Unlike sedative-hypnotic medications that artificially induce sleep through GABAergic inhibition, DSIP restores natural circadian sleep architecture by modulating the interplay between serotonergic, GABAergic, and glutamatergic neurotransmitter systems that govern sleep-wake transitions. Published research in subjects with disrupted sleep patterns reports improved sleep onset latency, increased total sleep time, and normalized sleep stage distribution including preserved REM cycling, suggesting restoration of physiological sleep regulatory mechanisms.
Initial effects within first month
Frequently Asked Questions
How should this peptide be stored?
DSIP in lyophilized form should be stored at -20°C for long-term stability, where it remains viable for up to 24 months. As a nine-amino-acid peptide containing tryptophan, DSIP is sensitive to light-induced oxidation — store protected from light in both lyophilized and reconstituted forms. Once reconstituted with bacteriostatic water, store at 2-8°C in amber vials and use within 21-30 days.
What quality controls are in place?
Every DSIP batch is independently tested by Janoshik Analytical Laboratory using HPLC for purity (99%+), mass spectrometry to confirm the complete Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu nonapeptide sequence (MW 848.8 Da), and amino acid composition analysis. Additional sterility and endotoxin testing ensure suitability for injectable research protocols. COAs documenting all test results are available for every batch.
Can I see the Certificate of Analysis?
Yes, Certificates of Analysis documenting HPLC purity, mass spectrometry identity confirmation, amino acid composition, sterility, and endotoxin results are available for every DSIP batch. You can find them on the product page under the Lab Results section, or contact support@pepcelllabs.com for specific batch documentation.
What is the shelf life after reconstitution?
Once reconstituted with bacteriostatic water, DSIP should be stored at 2-8°C protected from light and used within 21-30 days. The tryptophan residue at position 1 is the primary degradation-sensitive site — exposure to light or elevated temperatures accelerates its oxidation. For multi-week protocols, preparing single-use aliquots at reconstitution helps maintain consistent peptide integrity throughout the research period.
Is this product for human use?
DSIP is sold strictly for in-vitro research, laboratory use, and educational purposes. While DSIP was first characterized in 1977 and has been studied in limited human sleep research trials, it has not undergone comprehensive FDA-regulated clinical development and is not approved as a therapeutic agent. This product is not intended for human consumption or self-administration. Always consult applicable regulations in your jurisdiction.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
